NCT03133130View on ClinicalTrials.gov

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

February 14, 2018

Study Completion Date

February 14, 2018

Conditions
Hypertrophic Scar
Interventions
DRUG

BMT101

BMT101 is administered to 6 subjects in each of 4 groups.

DRUG

Placebo

Placebo is administered to 2 subjects in each of 4 groups.

Trial Locations (1)

06162

Hugel, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT03133130 - Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter